Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
Oligodeoxynucleotides containing unmethylated cytosine-phosphate-guanosine motifs (CpG-ODN) possess immunostimulatory effects and potential antitumor activity. Since the skin is an easily available site of administration of CpG-ODN due to its accessibility and the presence of abundant antigen presenting cells, it is expected that the application of CpG-ODN to the skin would induce systemic immune response and antitumor activity. However, it is difficult to deliver hydrophilic macromolecules including CpG-ODN through the skin. We have previously demonstrated that small interfering RNA (siRNA) was efficiently delivered into rat epidermis by iontophoresis. In this report, we investigate the effect of transdermal iontophoretic delivery of CpG-ODN on the induction of immune responses and antitumor activity against B16F1 melanoma in mice. Iontophoresis promoted CpG-ODN delivery into the epidermis and dermis. Furthermore, iontophoretic delivery of CpG-ODN to the skin induced the expression of proinflammatory and Th1-type cytokines in the skin and draining lymph node. Finally, transdermal iontophoretic delivery of CpG-ODN led to antitumor activity against B16F1 melanoma. Interestingly, the CpG-ODN administration site is not restricted to the tumor area. In conclusion, CpG-ODN delivered transdermally induced potent antitumor activity, and our system is expected to serve as a simple and noninvasive approach for cancer immunotherapy.
Graduate School of Life Science, Hokkaido University, Kita 12 Nishi 6, Kita-ku, Sapporo-City, Hokkaido 060-0812 Japan.
Kaoru
K
Kigasawa
Kazuaki
K
Kajimoto
Takashi
T
Nakamura
Susumu
S
Hama
Kiyoshi
K
Kanamura
Hideyoshi
H
Harashima
Kentaro
K
Kogure
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D000279:Administration, Cutaneous; D000818:Animals; D016207:Cytokines / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D007478:Iontophoresis; D008297:Male; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008812:Mice, Hairless; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D012867:Skin / Q000276:immunology / Q000473:pathology
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D016207:Cytokines; D009838:Oligodeoxyribonucleotides